Business
Sensus Healthcare to Showcase Commercial and Late-Stage Products at the American Academy of Dermatology Annual Meeting
BOCA RATON, Fla., March 06, 2025--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces it will be showcasing its full line of commercial Superficial Radiotherapy (SRT) products including the SRT-100®, SRT-100+ and SRT-100 Vision™ systems, along with several innovative pre-commercial products, at the 2025 American Academy of De
About this update from Sensus Healthcare, Inc.
[{"type":"text","content":"Full line of SRT products along with innovative pre-commercial products including portable lesion detection and TransDermal Infusion to be featured in a brand-new, A.I.-focused environment at Booth #2451","length":203,"tagName":"p","attribs":{}},{"type":"text","content":"BOCA RATON, Fla., March 06, 2025--(BUSINESS WIRE)--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces it will be showcasing its full line of commercial Superficial Radiotherapy (SRT) products including the SRT-100®, SRT-100+ and SRT-100 Vision™ systems, along with several innovative pre-commercial products, at the 2025 American Academy of Dermatology (AAD) Annual Meeting taking place March 7-11, 2025 at the Orange County Convention Center in Orlando, Florida.","length":637,"tagName":"p"},{"type":"text","content":"At Booth #2451, Sensus invites attendees to "The A.I. Experience," its brand new, futuristic, technology-focused environment specially designed to spotlight the Company’s innovations and technologies. Among the showcased products will be the SRT-100 Vision, the only FDA-cleared IG-SRT that’s increasingly being recognized by dermatologists as the non-surgical solution of choice for treating non-melanoma skin cancer and keloids. The booth will also showcase Sensus’ new prototype handheld ultrasound device, designed to help clinicians identify skin lesions and enhance practice efficiency, and its work-in-process TransDermal Infusion (TDI) product with Sentinel™ IT Solutions capabilities.","length":703,"tagName":"p"},{"type":"text","content":""We are excited to return to the AAD annual conference and share our passion for advancing skin health. This year more than ever we’ve got a number of exciting technologies and workflows to share with dermatologists, including a new handheld ultrasound device we’re developing to identify skin lesions, vastly expanding access to detection in a portable or remote setting," said Joe Sardano, Chairman and Chief Executive Officer of Sensus Healthcare. "I invite attendees to stop by our booth and experience our A.I.-supported demonstrations, explore our suite of technologies and learn how Sensus is advancing the standard of care ...